Skip to main content
. Author manuscript; available in PMC: 2019 Nov 11.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jul 21;130:113–130. doi: 10.1016/j.addr.2018.07.009

Table 3.

GLP-1 RAs pharmacokinetics parameters

Product
name		 Dose Tmax Vd T1/2 AUC CL Ref
Exenatide BID
Byetta®		 Single dose of 10 μg 2.1 h 28.3 L 2.4 h 1036 pg•h/ml 9.1 L/h [19]
Lixisenatide
Adlyxin®		 N.A. 1-3.5 h 100 L 3 h N.A. 35 L/h [25]
Liraglutide
Victoza®		 Single dose of 0.6 mg 8-12 h 13 L 13 h 960 ng•h/ml 1.2 L/h [20]
Semaglutide
Ozempic®		 Single dose of 0.5 mg 56 h 9.4 L 7 days 3123 nmol•h/L 0.039 L/h [34]
Albiglutide
Tanzeum®		 Single dose of 30 mg 3-5 d 11 L 5 days 465 μg•h/ml 0.067 L/h [23]
Dulaglutide
Trulicity®		 Multiple doses of 1.5 mg to steady state 24-72 h 17.4 L 5 days 14 μg•h/ml 1.07 L/h [24]
Exenatide QW
Bydureon®		 Multiple doses of 2 mg to steady state Css =300 pg/ml; Tss = 6~7 weeks [21]
ITCA 650 Continuous delivery of 20 μg/day Css = 75.8 pg/ml [42]

Abbreviations: Tmax: time to reach peak plasma concentration after administration; Vd: apparent volume of distribution; AUC: area under the curve for peptide concentration in plasma, CL: clearance; Css: average peptide concentration at the steady state; Tss: time to reach steady state after administration.